Search the Newsreel

Lake Street Initiates Verrica Pharmaceuticals at Buy With $9 Price Target

Lake Street Initiates Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Announces Target Price $9

Lake Street has initiated coverage on Verrica Pharmaceuticals (VRCA.US) with a Buy rating and set a price target of $9. This indicates an optimistic outlook from the analyst firm regarding the company's future performance.

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the Close - Dividend Increase Stocks

Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the Close - New Analyst Coverage

Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current Session - Guidance Revision Trend

Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current Session - Buyback Announcement Report

Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current Session - Margin Improvement Report

Verrica Pharmaceuticals Earnings Call: Growth Amid Losses

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

Analysts have issued a consensus "Hold" rating for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), with an average 12-month price target significantly higher than its current trading price. Institutional investors and hedge funds hold a substantial portion of the company's stock, with many increasing their positions recently. …

Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the Day - Return On Capital

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million …

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed …

VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its CEO purchase 25,000 shares, leading to a 7.5% after-hours price increase and renewed investor interest despite ongoing profitability challenges. While the GF Value™ suggests VRCA is 50.3% undervalued, this should be viewed cautiously given the company's negative …

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The …

Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Verrica Pharmaceuticals Inc.'s Interim CFO, John J. Kirby, purchased 5,000 shares of common stock in the open market on August 18, 2026. The shares were bought at a weighted average price of $4.93, with individual trades ranging from $4.85 to $4.99 per share. Following …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

Verrica (VRCA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jayson RiegerChief Medical Officer - Noah RosenbergInterim Chief Financial Officer - John KirbyChief Operating Officer - David ZawitzChief Commercial Officer - Chris …

VRCA Q2 2026 Earnings: Wider-Than-Expected Loss of $0.54 Sends Shares Down 3.54% - EPS Growth Report

Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade Persists - Rounding Bottom

Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals reported significant Q2 revenue growth for its YCANTH treatment, achieving $5.1 million in U.S. net product revenue. The company also provided updates on its common warts program, with pivotal Phase III trials underway and top-line results expected in mid-2027. Additionally, Verrica announced …

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) reported a wider-than-expected adjusted loss of $0.48 per share for the quarter, though revenue slightly exceeded forecasts at $5.86 million. The company saw strong sequential growth in YCANTH dispensed units and net product revenue, and began dosing patients in a pivotal …

Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary

Verrica Pharmaceuticals Inc. reported a significant decline in its financial performance for the quarter ended 2026, with revenue decreasing by 53.8% to $5.86M and a net loss of ($13.15M), resulting in a diluted EPS of ($0.62). This compares to a net income of $204K …

VRCA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Elevated Development Costs - Share Dilution Risk

VRCA|Verrica Pharmaceuticals Inc|Price:5.080|Chg%:-0.280

Verrica secures $27.5 million credit facility from chairman By Investing.com

Verrica Pharmaceuticals Inc. announced a $27.5 million credit facility with an entity controlled by its chairman and largest shareholder, Paul B. Manning. This financing includes an immediate $12.5 million and an additional $15 million upon reaching specific milestones. The funds will support the commercialization …

Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) reported a Q2 loss of $0.48 per share, which beat the Zacks Consensus Estimate of a $0.56 loss, representing a 14.29% surprise. The company's revenues for the quarter were $5.86 million, surpassing estimates by 1.77%, despite being lower than the …

Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Verrica Pharmaceuticals has secured a credit facility of up to $27.5 million with City National Bank, providing non-dilutive growth capital. This financing includes a $20 million term loan and a $7.5 million revolving credit facility. The capital is expected to support the commercial launch …

New funding supports Verrica's global Phase 3 common-warts program

Verrica Pharmaceuticals (Nasdaq: VRCA) has secured a new credit facility of up to $27.5 million in non-dilutive growth capital from an entity controlled by its Chairman, Paul B. Manning. This financing aims to support the commercialization of YCANTH, fund the global Phase 3 common …

YCANTH applicator units reach 19,626; common-wart data expected mid-2027

Verrica Pharmaceuticals reported Q2 2026 total revenue of $5.9 million, down from $12.7 million year-over-year, largely due to the absence of a one-time milestone payment. Despite this, U.S. YCANTH net product revenue grew to $5.1 million, with dispensed YCANTH applicator units increasing by 46.1% …

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Verrica Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a record demand for YCANTH® with 19,626 dispensed applicator units, an increase of 28.3% quarter-over-quarter and 46.1% year-over-year. Total revenue reached $5.9 million, including $5.1 million in U.S. YCANTH net product revenue. The company …

Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise